Oruka Therapeutics Inc (ORKA) Stock Price, Quote & News

Company Profile

Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. T...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 606 7910

Website: orukatx.com

Address:

855 Oak Grove Avenue, Suite 100, Menlo Park, United States

Pika_Capital Aug. 18 at 4:31 AM

$MTSR $ORKA $IMVT This is one of the wildest move ive ever made in bios. Proceeds from mtsr (buyout +100% gain) compounded +600% in orka and +200% in imvt. Trying to keep emotions in check though. It's very easy to lose everything in this sector.

2 · Reply

Whiskeyunderthebed Aug. 15 at 6:34 PM

$ORKA end of the Quarter roster:

0 · Reply

Whiskeyunderthebed Aug. 13 at 1:23 PM

$ORKA another whale just joined our pod-

0 · Reply

Quantumup Aug. 12 at 3:42 PM

BTIG Sees Positive Readthroughs to $JBIO (Buy-$77), $ORKA (Buy-$151), $SYRE (Buy-$132), CBIO (NR), and DMRA (NR) after ABBV (NR) & APGE (⬇️to Neutral) M&A. *Notes APGE as the First Successful Partnered Exit from Paragon Labs/Fairmount of the Group Mentioned Above. Here's what BTIG said in its note to investors: https://x.com/Quantumup1/status/2087565029822320875?s=20

0 · Reply

FlyingChemist01 Aug. 12 at 1:33 PM

$ORKA I will buy shares when goes down below 20$

3 · Reply

thesheiktrader Aug. 11 at 1:37 PM

$ORKA we have in front of us the future of psoriasis

1 · Reply

Stocktwits Aug. 10 at 5:17 PM

$ORKA Added to watchlist ⌚

0 · Reply

MaverikIT Aug. 10 at 5:08 PM

$ORKA - eyeing 52wk$ @cynicaloptimist @WAJeff @BustaCapital @Jblack500 @howardlindzon @IsabellaDC @No_Face_character

1 · Reply

STRelativeStrength Aug. 10 at 5:06 PM

$ORKA undiscovered breakout with 412 watchers

0 · Reply

Pika_Capital Aug. 10 at 3:27 PM

$ORKA $SYRE they will most likely be gone too for a nice premium after $APGE riding it through

1 · Reply

Oruka Therapeutics reports Q2 EPS (55c), consensus (50c)

Aug 10, 2026, 7:03 AM EDT - 9 days ago

Oruka Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Aug 10, 2026, 7:00 AM EDT - 9 days ago

Oruka Therapeutics Earnings release: Q2 2026

Aug 10, 2026, 7:00 AM EDT - 9 days ago

Oruka Therapeutics Quarterly report: Q2 2026

2026-07-02T14:05:25.000Z - 6 weeks ago

Oruka Therapeutics falls -8.1%

2026-07-01T11:10:49.000Z - 7 weeks ago

Oruka Therapeutics price target raised to $130 from $100 at UBS

Jun 3, 2026, 3:45 PM EDT - 2 months ago

Oruka Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

Jun 2, 2026, 11:00 AM EDT - 2 months ago

Oruka Therapeutics Transcript: AGM 2026

May 28, 2026, 8:00 AM EDT - 2 months ago

Oruka Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference

2026-05-13T20:31:09.000Z - 3 months ago

Oruka Therapeutics reports Q1 EPS (48c), consensus (54c)

May 13, 2026, 4:03 PM EDT - 3 months ago

Oruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 13, 2026, 7:00 AM EDT - 3 months ago

Oruka Therapeutics Quarterly report: Q1 2026

May 13, 2026, 7:00 AM EDT - 3 months ago

Oruka Therapeutics Earnings release: Q1 2026

2026-05-07T06:12:19.000Z - 3 months ago

Halozyme licenses Hypercon technology to Oruka Therapeutics in psoriasis

HALO

May 6, 2026, 8:00 AM EDT - 3 months ago

Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology

HALO

2026-04-30T10:05:54.000Z - 3 months ago

Oruka Therapeutics price target raised to $120 from $109 at Leerink

2026-04-29T10:23:22.000Z - 4 months ago

Oruka Therapeutics price target raised to $120 from $75 at H.C. Wainwright

2026-04-28T23:45:20.000Z - 4 months ago

Oruka Therapeutics $700M Secondary priced at $72.50

Apr 28, 2026, 7:42 PM EDT - 4 months ago

Oruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public Offering

2026-04-28T12:29:34.000Z - 4 months ago

Oruka Therapeutics price target raised to $100 from $75 at UBS

2026-04-27T20:30:08.000Z - 4 months ago

Oruka Therapeutics announces $500M common stock, warrants offering

Apr 27, 2026, 4:17 PM EDT - 4 months ago

Oruka Therapeutics Announces Proposed $500 Million Underwritten Public Offering

2026-04-27T20:15:11.000Z - 4 months ago

Oruka Therapeutics price target raised to $131 from $71 at Clear Street

2026-04-27T16:08:26.000Z - 4 months ago

Oruka Therapeutics rises 19.0%

2026-04-27T15:46:42.000Z - 4 months ago

Oruka Therapeutics price target raised to $160 from $78 at Barclays

2026-04-27T15:46:21.000Z - 4 months ago

Oruka Therapeutics price target raised to $165 from $85 at Wedbush

2026-04-27T15:30:18.000Z - 4 months ago

Oruka Therapeutics price target raised to $200 from $125 at Guggenheim

2026-04-27T14:34:43.000Z - 4 months ago

Oruka Therapeutics rises 23.5%

2026-04-27T14:25:09.000Z - 4 months ago

Oruka Therapeutics price target raised to $151 from $78 at BTIG

Apr 27, 2026, 8:00 AM EDT - 4 months ago

Oruka Therapeutics Transcript: Status update

Apr 27, 2026, 8:00 AM EDT - 4 months ago

Oruka Therapeutics Press release: Status update

Apr 27, 2026, 8:00 AM EDT - 4 months ago

Oruka Therapeutics Slides: Status update

Apr 27, 2026, 7:00 AM EDT - 4 months ago

Oruka Therapeutics Announces Positive Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Phase 2a Trial in Moderate-to-Severe Plaque Psoriasis

Apr 26, 2026, 12:00 PM EDT - 4 months ago

Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Trial on April 27, 2026

Apr 17, 2026, 8:00 AM EDT - 4 months ago

Oruka Therapeutics Proxy statement: Proxy filing

Apr 17, 2026, 8:00 AM EDT - 4 months ago

Oruka Therapeutics Proxy statement: Proxy filing

Apr 2, 2026, 8:00 AM EDT - 4 months ago

Oruka Therapeutics Registration statement: Registration filing

Mar 12, 2026, 4:05 PM EDT - 5 months ago

Oruka Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Mar 12, 2026, 7:00 AM EDT - 5 months ago

Oruka Therapeutics Earnings release: Q4 2025

Mar 12, 2026, 7:00 AM EDT - 5 months ago

Oruka Therapeutics Annual report: Q4 2025

Mar 11, 2026, 1:00 PM EDT - 5 months ago

Oruka Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Feb 9, 2026, 7:00 AM EST - 6 months ago

Oruka Therapeutics to Participate in Multiple Upcoming Conferences

Jan 15, 2026, 12:00 PM EST - 7 months ago

Oruka Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 7:00 AM EST - 7 months ago

Oruka Therapeutics Announces Positive Interim Phase 1 Data for ORKA-002 and Initiation of EVERLAST-B Trial of ORKA-001

Jan 12, 2026, 7:00 AM EST - 7 months ago

Oruka Therapeutics Slides: Corporate presentation

Jan 6, 2026, 7:00 AM EST - 8 months ago

Oruka Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 11, 2025, 4:01 PM EST - 8 months ago

Oruka Therapeutics Announces New Board Member and Board Transition

Nov 12, 2025, 4:05 PM EST - 9 months ago

Oruka Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 12, 2025, 4:00 PM EST - 9 months ago

Oruka Therapeutics Earnings release: Q3 2025

Nov 12, 2025, 4:00 PM EST - 9 months ago

Oruka Therapeutics Quarterly report: Q3 2025

Nov 11, 2025, 4:40 PM EST - 10 months ago

Oruka Therapeutics Transcript: Stifel 2025 Healthcare Conference

Oct 29, 2025, 7:00 AM EDT - 10 months ago

Oruka Therapeutics to Present at Multiple November Investor Conferences

Oct 14, 2025, 8:00 AM EDT - 11 months ago

Oruka Therapeutics Registration statement: Registration Filing

Oct 14, 2025, 8:00 AM EDT - 11 months ago

Oruka Therapeutics Registration statement: Registration Filing

Oct 3, 2025, 8:00 AM EDT - 11 months ago

Oruka Therapeutics Registration statement: Registration Filing

Oct 3, 2025, 8:00 AM EDT - 11 months ago

Oruka Therapeutics Registration statement: Registration Filing

Sep 18, 2025, 7:15 AM EDT - 11 months ago

Oruka Therapeutics Slides: Study Presentation

Sep 18, 2025, 7:00 AM EDT - 11 months ago

Oruka Therapeutics Slides: Corporate Presentation

Sep 18, 2025, 7:00 AM EDT - 11 months ago

Oruka Therapeutics Slides: Study Presentation

Sep 17, 2025, 1:02 AM EDT - 1 year ago

Oruka Therapeutics Announces $180 Million Private Placement

Sep 17, 2025, 1:00 AM EDT - 1 year ago

Oruka Therapeutics Announces Positive Interim Phase 1 Results for ORKA-001

Aug 11, 2025, 4:04 PM EDT - 1 year ago

Oruka Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 11, 2025, 7:00 AM EDT - 1 year ago

Oruka Therapeutics Earnings release: Q2 2025

Aug 11, 2025, 7:00 AM EDT - 1 year ago

Oruka Therapeutics Quarterly report: Q2 2025

Jul 21, 2025, 7:00 AM EDT - 1 year ago

Oruka Therapeutics Announces IND Clearance for EVERLAST-A Phase 2a Trial of ORKA-001 in Psoriasis with Phase 1 Data to be Presented at EADV in September

Jul 1, 2025, 4:01 PM EDT - 1 year ago

Oruka Therapeutics Announces Promotion of Laura Sandler to Chief Operating Officer

May 21, 2025, 7:00 AM EDT - 1 year ago

Oruka Therapeutics to Present at the Jefferies Global Healthcare Conference

May 20, 2025, 4:01 PM EDT - 1 year ago

Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-002, its Novel Half-life Extended Anti-IL-17A/F Antibody

May 14, 2025, 4:15 PM EDT - 1 year ago

Oruka Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 14, 2025, 12:00 AM EDT - 1 year ago

Oruka Therapeutics Quarterly report: Q1 2025

Apr 29, 2025, 7:00 AM EDT - 1 year ago

Oruka Therapeutics to Present at Bank of America Securities 2025 Health Care Conference

Apr 18, 2025, 8:00 AM EDT - 1 year ago

Oruka Therapeutics Proxy statement: Proxy Filing

Apr 18, 2025, 8:00 AM EDT - 1 year ago

Oruka Therapeutics Proxy statement: Proxy Filing

Mar 7, 2025, 8:30 AM EST - 1 year ago

Oruka Therapeutics Announces Preclinical Data for ORKA-002 at the 2025 American Academy of Dermatology Annual Meeting

Mar 6, 2025, 4:09 PM EST - 1 year ago

Oruka Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mar 5, 2025, 6:00 PM EST - 1 year ago

Oruka Therapeutics Earnings release: Q4 2024

Mar 5, 2025, 6:00 PM EST - 1 year ago

Oruka Therapeutics Annual report: Q4 2024

Mar 4, 2025, 10:30 AM EST - 1 year ago

Oruka Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 19, 2025, 7:00 AM EST - 1 year ago

Oruka Therapeutics to Present at Multiple March Investor Conferences

Dec 19, 2024, 7:00 AM EST - 1 year ago

Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody

Dec 18, 2024, 7:00 AM EST - 1 year ago

Oruka Therapeutics to be Added to the Nasdaq Biotechnology Index (NBI)

Nov 14, 2024, 7:00 AM EST - 1 year ago

Oruka Therapeutics Registration statement: Registration Filing

Nov 13, 2024, 4:25 PM EST - 1 year ago

Oruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 13, 2024, 7:00 AM EST - 1 year ago

Oruka Therapeutics Quarterly report: Q3 2024

Nov 13, 2024, 7:00 AM EST - 1 year ago

Oruka Therapeutics Earnings release: Q3 2024

Oct 18, 2024, 8:00 AM EDT - 1 year ago

Oruka Therapeutics Proxy statement: Proxy Filing

Oct 7, 2024, 8:00 AM EDT - 2 years ago

Oruka Therapeutics Proxy statement: Proxy Filing

Sep 25, 2024, 7:08 AM EDT - 2 years ago

Oruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of Dermatology and Venereology Congress

Sep 12, 2024, 7:05 AM EDT - 2 years ago

Oruka Therapeutics Announces $200 Million Private Placement

Aug 29, 2024, 4:50 PM EDT - 2 years ago

ARCA biopharma Announces Completion of Merger with Oruka Therapeutics and Implementation of Reverse Stock Split

Aug 26, 2024, 7:30 PM EDT - 2 years ago

ARCA biopharma Provides Update Regarding Special Dividend Amount in Connection with the Proposed Merger with Oruka Therapeutics

Aug 23, 2024, 4:30 PM EDT - 2 years ago

ARCA biopharma Announces 1-for-12 Reverse Stock Split in Connection with the Proposed Merger with Oruka Therapeutics

Aug 16, 2024, 4:15 PM EDT - 2 years ago

ARCA biopharma Declares Special Dividend in Connection with the Proposed Merger with Oruka Therapeutics

Aug 1, 2024, 4:15 PM EDT - 2 years ago

ARCA biopharma Announces Second Quarter 2024 Financial Results and Provides Corporate Update

May 10, 2024, 6:34 PM EDT - 2 years ago

ARCA BIOPHARMA INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ARCA biopharma, Inc. - ABIO

Apr 25, 2024, 4:15 PM EDT - 2 years ago

ARCA biopharma Announces First Quarter 2024 Financial Results and Provides Corporate Update

Apr 5, 2024, 1:27 PM EDT - 2 years ago

ARCA BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ARCA biopharma, Inc. - ABIO

Apr 3, 2024, 11:38 AM EDT - 2 years ago

Arca Biopharma stock ($ABIO) soars on merger news

Apr 3, 2024, 7:30 AM EDT - 2 years ago

ARCA biopharma and Oruka Therapeutics Announce Merger Agreement

Feb 1, 2024, 4:35 PM EST - 2 years ago

ARCA biopharma Announces 2023 Financial Results

Dec 19, 2023, 7:00 AM EST - 2 years ago

Oruka Therapeutics Proxy statement: Proxy Filing

Dec 19, 2023, 7:00 AM EST - 2 years ago

Oruka Therapeutics Proxy statement: Proxy Filing

Oct 18, 2023, 4:25 PM EDT - 3 years ago

ARCA biopharma Announces Third Quarter 2023 Financial Results

Jul 21, 2023, 4:25 PM EDT - 3 years ago

ARCA biopharma Announces Second Quarter 2023 Financial Results

Apr 24, 2023, 4:25 PM EDT - 3 years ago

ARCA biopharma Announces First Quarter 2023 Financial Results

Feb 24, 2023, 4:20 PM EST - 3 years ago

ARCA biopharma Announces 2022 Financial Results and Provides Corporate Update

Pika_Capital Aug. 18 at 4:31 AM

2 · Reply

Whiskeyunderthebed Aug. 15 at 6:34 PM

$ORKA end of the Quarter roster:

0 · Reply

Whiskeyunderthebed Aug. 13 at 1:23 PM

$ORKA another whale just joined our pod-

0 · Reply

Quantumup Aug. 12 at 3:42 PM

0 · Reply

FlyingChemist01 Aug. 12 at 1:33 PM

$ORKA I will buy shares when goes down below 20$

3 · Reply

thesheiktrader Aug. 11 at 1:37 PM

$ORKA we have in front of us the future of psoriasis

1 · Reply

Stocktwits Aug. 10 at 5:17 PM

$ORKA Added to watchlist ⌚

0 · Reply

MaverikIT Aug. 10 at 5:08 PM

$ORKA - eyeing 52wk$ @cynicaloptimist @WAJeff @BustaCapital @Jblack500 @howardlindzon @IsabellaDC @No_Face_character

1 · Reply

STRelativeStrength Aug. 10 at 5:06 PM

$ORKA undiscovered breakout with 412 watchers

0 · Reply

Pika_Capital Aug. 10 at 3:27 PM

$ORKA $SYRE they will most likely be gone too for a nice premium after $APGE riding it through

1 · Reply

FlyingChemist01 Aug. 10 at 2:57 PM

$ORKA $MLTX that company lives off hype. Basically an overpriced phase 2 promise with an avg 30% success rate for phase 2 companies. If the mAb with extended life will have serious side effects which are common for mAbs the patient will have to endure a long period of suffering out of those symptoms. That will be no good. It's way to early for supporting such a price action, that is just speculation based on a promise, guaranteed if something goes wrong it will plumb down -90%. Remember: globally phase 2 companies have a 30% success rate.

1 · Reply

StockQB Aug. 10 at 2:53 PM

$ORKA up after disappointing $MLTX PA trial results at 16weeks

0 · Reply

Whiskeyunderthebed Aug. 5 at 1:12 PM

$ORKA institutions just can't get enough of this

0 · Reply

Whiskeyunderthebed Jul. 25 at 11:07 PM

$ORKA soon to be released 28 week results

1 · Reply

Spicy_Trade Jul. 19 at 11:57 PM

Oruka Therapeutics, Inc. ( $ORKA ) SpicyTrade - Daily Stock Analysis https://youtu.be/1XnW94OCpSo?si=0wwZyRYA8oBIiACy

0 · Reply

mlanthoo Jul. 18 at 12:49 PM

$ORKA heavy volume on Friday

0 · Reply

Pika_Capital Jul. 17 at 5:43 PM

$ORKA $APGE $SYRE Holy moly what a run. In less than a year orka and syre jumped +500%, and apge was bought out. +250% And honestly if it was not about my man Oneil Trader (Growth Stock Forum sub on Seeking Alpha) I probably would not have gotten into these names. Give it a try if you want to grow as biotech investor. SA is full of shit as a platform but he does not want to pivot elsewhere for now. I brought in few guys and noone really complained. If you are reading this and did sub because of my recommendation, comment below and share feedback

0 · Reply

Gemola Jul. 17 at 5:07 PM

$ORKA First target $93.25 boolish

0 · Reply

Whiskeyunderthebed Jul. 17 at 3:02 PM

$ORKA another whale came in this morning for 1.2M shares.

0 · Reply

svedding Jul. 11 at 6:03 AM

$ORKA https://seekingalpha.com/article/4921257-oruka-therapeutics-intriguing-long-acting-psoriasis-programs-may-need-further-derisking

1 · Reply

Whiskeyunderthebed Jul. 10 at 6:00 PM

$ORKA a new whale just joined the pod

0 · Reply

OG_bull26 Jul. 8 at 7:26 PM

$ORKA UBS did a bad job… not moving since they rate

0 · Reply

Market Cap	7.46B
Revenue (ttm)	0.00
Net Income (ttm)	-105.43M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	496,991
Avg Vol	1,264,628
Day's Range	N/A - N/A
Shares Out	66.21M
Stochastic %K	99%
Beta	-0.34
Analysts	Strong Sell
Price Target	$148.15